#blood cancer approved drugs

[afeelgoodblog]

The Best News of Last Week - October 30, 2023

1. Bill to Ban Hidden Fees in California Signed into Law

California Attorney General Rob Bonta has released a statement regarding the signing of Senate Bill 478 (SB 478). SB 478, coauthored by Senators Bill Dodd and Nancy Skinner, will eliminate hidden fees, also known as 'junk fees,' in California starting from July 1, 2024. Hidden fees are deceptive charges that sellers include in transactions, either through obscured disclosures or later revelations, impacting consumers negatively.

2. New Portable Water Treatment System Vaporizes 99% of ‘Forever Chemicals’

A startup based Washington has devised a portable system capable of removing the vast majority of per- and polyfluoroalkyl substances, or PFAS, from water.

The system uses hydrothermal alkaline treatment, or HALT, to eliminate 99% of forever chemicals from water.

3. Tumor-destroying sound waves receive FDA approval for liver treatment in humans

The U.S. Food and Drug Administration has approved the use of sound waves to break down tumors—a technique called histotripsy—in humans for liver treatment. Technique developed at the University of Michigan provides a noninvasive alternative to surgery, chemotherapy and radiation treatments for cancer

4. Japan's top court says trans sterilisation requirement unconstitutional

Japan's Supreme Court has ruled that it is unconstitutional to require citizens to be sterilised before they can officially change genders.

The 2004 law said people could only change their gender if they have no reproductive capacity. Wednesday's ruling came after a transgender woman filed a petition challenging the law.

5. Abandoned golf courses are being reclaimed by nature

Golf courses, despite occupying large green spaces, are not necessarily good for the environment.

Conservation nonprofits and local authorities are looking to acquire golf courses that have been abandoned due to high maintenance costs, low player numbers or other reasons, and repurpose them into landscapes that boost biodiversity and build natural defenses against climate change.

6. NSW court allows health officials to give blood transfusion to Jehovah's Witness toddler

Regional New South Wales health officials have won a court order authorising them to give a blood transfusion to a Jehovah's Witness toddler if needed in surgery. The Supreme Court has been told the girl, three, who can only be referred to as JI, is in need of two surgical procedures. 

On such an application, the overriding criterion to be applied by the court is the best interests and welfare of the child.

7. North Atlantic right whale population has steadied, scientists say

The population of critically endangered North Atlantic right whales appears to have levelled off after a decade of steep decline, according to updated data released this morning by Canadian and American scientists. Scientists in the consortium said Monday that the 2021 estimate of 340 North Atlantic right whales in existence has been recalculated to 365 primarily because of the number of calves born that year.

The estimate for 2022 is 356.

---

That's it for this week :)

This newsletter will always be free. If you liked this post you can support me with a small kofi donation here:

Buy me a coffee ❤️

Also don��t forget to reblog this post with your friends.

[macgyvermedical]

Hey babe, wanna hear something hot? *whispers* history of metformin

Ok okay I'll talk

So metformin is commonly thought of as the most boring of diabetes drugs. Like, everyone who has ever thought about maybe having type 2 diabetes is taking it unless it gives them diarrhea, and even then their doctor still probably wants them to take it. But it's a first line because it's old, it's cheap, it doesn't often cause hypoglycemia, and it has relatively few side effects compared to other diabetes drugs. Also, like a lot of older drugs, it does way more than it says on the packaging. And a lot of stuff we're still learning about.

In order to talk about metformin, we have to talk about a plant called goat's rue. Goat's rue is a plant native to Europe, Africa, and Asia, and currently grows just about everywhere. In ancient times it was used as an anti-parasitic, a plague remedy, and to relieve the excessive urination caused by what might have been diabetes. In 1918 it was found to contain a chemical called galegine, which did lower blood sugar. Galegine as an anti-diabetes medication is probably too toxic to use long term. However, with a few chemical tweaks, it could become a drug that lowered blood sugar without the toxic effects. Metformin was born.

Metformin came out in 1923 and is a type of drug called a biguanide. it's actually the only type in it's class still available as an anti-diabetic agent, because the other drugs in it's class that came out in the 1920s and 30s caused lactic acidosis and liver problems (similar to the types of reactions seen with galegine), and were taken off the market.

Metformin (and pretty much all oral antidiabetic agents in development at this time) didn't do well initially, probably because they came out the same decade as insulin, and insulin was a lot more effective at treating any kind of diabetes.

It fell out of use extremely quickly, and didn't get picked up again until the 1940s, when US access to antimalarial drugs was cut off, just as a war in the pacific was ramping up. Metformin was evaluated as an antimalarial during WWII, and while noted to have some anti-malarial properties (particularly as a malaria preventative) it also was noted to significantly lower blood sugar in diabetic patients- while not lowering blood sugar very much at all in non-diabetic patients.

This effect, rather than it's antimalarial properties, was what got scientists really interested. Unfortunately, it would not be until 1957 in France that metformin had its first major studies to determine that it did, indeed, work against diabetes. Metformin lost the race to the "first" (successful) oral antidiabetic agent by a year, to a different drug that was found while looking for a new antibiotic- Diabenese.

Metformin became a commercial success in France, while Diabenese became successful in the United States. Metformin would actually not be approved for use in the US until 1995.

But now we get to talk about what metformin does and why it's so freaking cool.

Type 2 Diabetes- lowers A1C (a measure of blood sugar control) by 1-2 full points

Prevents/reverses weight gain due to antipsychotics

Prevents and treats malaria

Makes the flu shot work better

Decreases severity of respiratory illness and complications related to the flu

Changes gut microbiome for the better

Regulates periods and reduces other symptoms in people with PCOS

Lowers risk of breast, colon, and prostate cancer

Lowers risk of dementia

Lowers risk of stroke

May increase lifespan

[mindblowingscience]

The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive activation and cytokine-independent signaling and underlie several hematological malignancies from myeloproliferative neoplasms (MPN) to acute leukemia and lymphomas. JAK2 contains an active kinase domain and an inactive pseudokinase domain. Interestingly, pathogenic mutations mainly occur in the regulatory pseudokinase domain. Due to its critical pathogenic role, JAK2 has become an important therapeutic target. The four currently approved JAK2 inhibitors relieve symptoms but do not heal the patient or affect survival. These drugs target the highly conserved kinase domain and affect both normal and mutated JAK2 and, due to side effects, carry a black box warning that limits their use in elderly, cardiac and cancer patients. The selective inhibition of pathogenic JAK2 is a key pending goal in drug discovery that requires a precise mechanistic understanding of the regulation of JAK2 activation.

Continue Reading.

[thetepes]

Thalidomide baby: Referencing children born with birth defects caused by the use of a drug called Thalidomide, sold under the brand names Contergan and Thalomid among others, a medication that was prescribed to pregnant women in the 1950s and 1960s.

Thalidomide was promoted for anxiety, trouble sleeping, "tension", and morning sickness. While it was initially thought to be safe in pregnancy, concerns regarding birth defects arose, resulting in its removal from the market in Europe in 1961. Common side effects include sleepiness, rash, and dizziness. Severe side effects include tumor lysis syndrome, blood clots, and peripheral neuropathy. Thalidomide is a known human teratogen and carries an extremely high risk of severe, life-threatening birth defects if administered during pregnancy. It causes skeletal deformities such as amelia (absence of legs and/or arms), absence of bones, and phocomelia (malformation of the limbs). A single dose of thalidomide, regardless of dosage, is enough to cause teratogenic effects. 

The total number of infants severely harmed by thalidomide use during pregnancy is estimated at over 10,000, possibly 20,000, of whom about 40% died around the time of birth. Those who survived had limb, eye, urinary tract, and heart problems. The birth defects caused by thalidomide led to the development of greater drug regulation and monitoring in many countries.

It was approved in the United States in 1998 for use as a treatment for cancer.

[wickedsrest-rp]

Name: Katherine “Kit” Clarke Species: Vampire (previously spawn vampire) Occupation: Unemployed Age: 74 Years Old (Looks about 36) Played By: Chayya Face Claim: Ruth Negga

"A little party never killed nobody… Oh, wait. Never mind."

TW: Terminal illness (breast cancer), drug abuse

Don’t believe the tabloids, okay, Kit Clarke grew up in a perfectly normal household just south of Hoboken, New Jersey. Just them and their mom and their dad and the both of them were doctors, if you can believe it. Brain-numbingly normal. They wanted the best for Kit and were often able to provide. When they started to show a real aptitude and love for music, they took that into account with piano lessons, voice training, and a gorgeous acoustic guitar. Overall, the Clarke household was loving, if ambitious, and as long as they got good grades, Kit was able to pursue their own interests as well. 

But they were, still, eventually, a teenager, and one with a fun-seeking edge. Growing up where they did, it wasn’t hard at all to sneak into the City. It was innocent, for the most part – exploring the city, watching the people and, of course, checking out the music venues. Any club that would let a kid so obviously underage come in was on Kit’s radar and they become a regular. And when they had open mics, well, how could they resist?

And that’s how Kit met Matty. He heard them sing in some crappy, hole-in-the-wall club that he had snuck out to and the rest is history. Or, at least, the rest is better left to be hashed out by VH1’s Behind the Music and MTV’s Where Are They Now?

Matty and Kit ran deep, quickly, and it wasn’t long before they were putting together a band. It was just smashing around, in those early days, just jamming and giggling and making dreamy-eyed plans. Kit’s parents Did Not Approve, but, hey, they were still keeping their grades up so they let it go. But then Kit told them that they were skipping out on college, that the band had actually landed some gigs and they wanted to make a real go of it. They may have had dreams of them becoming a doctor, like them, or something else stable and steady and normal, but Kit was eighteen by then and they done this to themselves in some sense. They raised Kit to be independent and ambitious and unapologetic and that’s how they ran off with the band. 

And god, it was good. It was amazing. It was more than Kit ever could have imagined, traveling the country with this band that was easily becoming a second family. Making music and playing it and having people like it. Insane. And they got to do it all with their best friend. It was cosmic shit, what they were doing and  they loved every second it (except maybe the fucking tabloids but, well, every rose, right?). It was a whirlwind boardwalk ride and through it all Kit wrote letters to their parents, sent them money even though they didn’t need it. They wrote back asking if they were okay, asking when they would be coming home next, tentatively trying to address the rumors they had read about drugs in the band.

And then Matty was turned and that sure was a trip. Kit was the one who found him, crazed and bloody and with no heartbeat in some alleyway. But just like everything else, they figured it out, together, as a band, as a family. And it turned out they all rocked through it. Diamondbacks charged on. And now they had proof they could outlast anything. 

Until Kit’s diagnosis came in.

It was triple-negative and it had spread and they could try chemotherapy but their odds weren’t good. And then they tried the chemotherapy and it was awful, they’ve never felt so sick. They stopped the treatment, wanting to go home and die in peace. Except that wasn’t the plan at all because they had, shamefully, asked Matty to turn them and he agreed. Only it all went wrong.

Forty years of nothing. Forty years of just blood and cravings and hunger and instinct and hunting. Forty years of feed, feed, feed, with only the barest brush of comfort from Matty at the edges of their consciousness, in their bond.

Coming back was excruciating. Regaining their mind, regaining control and full consciousness. It all hurts and it’s all hard, even with Matty by their side.

Character Facts:

Personality: Fun-loving, friendly, compassionate, goofy, musical, ambitious, tempestuous, avoidant, wary

Happily responds to any pronouns but prefers “they” and “she.”

A founding member of The Diamondbacks with Matty, Kit was one of the key lyricists and bassists and would often lend a hand on vocals. They can also play guitar and keyboard well, but their instrumental prowess is nowhere near Matty’s virtuoso talent. 

To the rest of the world, Kit died in 1983 from breast cancer. Only those in the band know what truly happened.

Yes, they still talk with a North Jersey accent, whadda ya gonna do aboudit?

They’ve technically not been around for the past 40 years or so there’s a lot for them to adjust to and learn. No one tell them about that other guy who’s singing in Van Halen.

[spiritualdirections]

"For the first time, an oral contraceptive is going to be available over the counter, without a prescription. On July 13, the Food and Drug Administration (FDA) announced that it has approved the contraceptive pill Opill. Many are praising the FDA’s decision as a significant step toward making contraception more widely available. Perrigo Company, the pill's Dublin-based manufacturer, stated that Opill will most likely be available in grocery and convenience stores, as well as online, in early 2024. Perrigo’s president and CEO Murray Kessler called the FDA’s decision “a new, groundbreaking chapter in reproductive health.”  "It may indeed be groundbreaking—but not for the reason Kessler believes. Contrary to popular myth, increased use of contraception is correlated to an increase in abortions. And despite what proponents claim, hormonal birth control has a damaging effect on both mental and physical health...Opill, like other forms of hormonal birth control, primarily consists of progestin, “a hormone that thickens mucus in the cervix to make it harder for sperm to enter the uterus,” according to the New York Times. Opill is said to be less effective than pills with both progestin and estrogen, yet defenders of the FDA’s decision say that Opill is still highly effective as long as it is taken at the same time every day."

The article makes the point, which everyone who studies this knows, that the pill actually increases nonmarital pregnancies, because the pill requires regular use, and the kind of people who are not disciplined enough to wait until marriage are often also not disciplined enough to take a pill every day. This version of the pill seems to require an extraordinary high level of discipline--it must be taken at the same time every day. "Unintended" pregnancies in the U.S. basically never occur because contraceptives aren't available, but because the couple does not use them properly.

The article also makes the point about the extensively documented link between the pill and depression, which I've blogged about before. It might have mentioned the link between the pill and blood clotting, which might be dangerous if the pill is taken over the counter and the user is not in touch with a doctor.

The article does not make a point that it easily could have, that this is a huge win for Big Pharma. Notice that it is the CEO who calls this "groundbreaking." I'm assuming the Biden administration will get its fair share of donations this cycle.

The article also does not discuss something that I think is relevant. Typical birth control pills are on the list of known carcinogens by the International Agency for Research for Canger (IARC), a project of the World Health Organization. They are in category 1, the same as tobacco. It's likely that the explosion in cases of breast cancer over the last 50 years is caused by increasingly widespread use of the hormones in the pill. The CDC says that using the pill increases a woman's chances of breast and cervical cancers by as much as 60%. As I wrote a few years ago, "It’s safer to smoke 5-8 cigars daily (relative risk of cancer 1.17; see Table 3)–which almost nobody does–than to be on the Pill (relative risk 1.24 for current users)." 

(The article does not say more about whether the reduced amount of estrogen is intended to make Opill less carcinogenic, but I can't imagine that we have sufficient data on this particular pill to determine this.)

The argument for having restrictions on tobacco sales is that tobacco causes cancer. The same argument should argue for at least the same restrictions on Opill. Defenders of the pill will point to studies that show the likelihood of cancer drops off once someone stops using the pill (as in the CDC link above); the likelihood of cancer also drops off once someone quits smoking cigarettes. Given these parallels, I would think that states would want to pass laws restricting over the counter sales of either carcinogen to minors.

The more people become aware that playing with the hormones in the body is not that safe, the more people will switch to using fertility awareness methods, which are natural and more in tune with the environment. But these natural methods don't make Big Pharma any money!

[particularj]

This is huge.

Biden is directing the power of HHS and Medicare / Medicaid’s purchasing & approval power to force drug makers to negotiate lower prices or risk steep penalties. And they (begrudgingly and after filing lawsuits) agreed to negotiate!

Why? The penalty if they didn’t, they’d have to pay 65-95% taxes on drug sales or withdraw ALL of their companies’ drugs from the formulary.

The government is pushing to cut prices 25% by 2026, which would save billions annually.

The first round includes 10 high-demand, brand name drugs without generics despite years of being on the market, and for conditions such as high blood pressure, diabetes, and cancer. In other words, these are life-saving drugs.

By pushing price cuts, it can show how drug manufacturers CAN lower prices across the market, because they are making money hand over fist.

The irony? A drug manufacturer spokesperson indicated this ‘choice’ to negotiate wasn’t a fair or real choice. Oh? Like the choice between buying your blood pressure medication or your diabetes medication, because of how much y’all charge? Or maybe between all of their meds and their heat? Hmm?

Get fucked drug makers. You have blood on your hands and you use the idea that you are good people making medicine for people to cover the fact you are even more greedy than the average company by profiteering on a product people literally can’t live without. Universal healthcare for all.

[spooniestrong]

Why you should avoid kava and 9 other risky dietary supplements

One-third of Americans say they believe supplements have been tested by the Food and Drug Administration for safety, according to a 2022 nationally representative survey by Consumer Reports of 3,070 adults in the United States. But the FDA doesn’t approve or test the safety or effectiveness of any supplement before it enters the U.S. market.

After consulting with a panel of doctors and researchers, Consumer Reports says you should avoid these 10 risky supplements. In general, risk increases the larger the dosage and the longer the supplement is taken. Also beware of illegal or unapproved drug ingredients, such as tianeptine, methylsynephrine and phenibut.

Chaparral

Also called: creosote bush, greasewood, Larrea divaricata, Larrea tridentata, larreastat

Claimed benefits: weight loss; eases inflammation; treats colds, infections, rashes, cancers

Potential harms: kidney problems, liver damage

Coltsfoot

Also called: coughwort, Farfarae folium leaf, foalswort, Tussilago farfara

Claimed benefits: relieves cough, sore throat, laryngitis, bronchitis, asthma

Potential harms: liver damage, possible carcinogen

Comfrey

Also called: blackwort, bruisewort, slippery root, Symphytum officinale

Claimed benefits: relieves cough, heavy menstrual periods, stomach problems, chest pain; treats cancer

Potential harms: liver damage, cancer

Germander

Also called: Teucrium chamaedrys, Teucrium viscidum

Claimed benefits: weight loss; alleviates fever, arthritis, gout, stomach problems

Potential harms: liver damage, hepatitis

Greater celandine

Also called: celandine, Chelidonium majus

Claimed benefits: alleviates stomach ache

Potential harms: liver damage

Kava

Also called: ava pepper, kava kava, Piper methysticum

Claimed benefits: eases anxiety, helps sleep

Potential harms: liver damage, exacerbates Parkinson’s disease and depression, impairs driving

Lobelia

Also called: asthma weed, Lobelia inflata, vomit wort, wild tobacco

Claimed benefits: helps respiratory problems, smoking cessation

Potential harms: nausea, vomiting, diarrhea, tremors, rapid heartbeat, confusion, seizures, hypothermia, coma

Pennyroyal oil

Also called: Hedeoma pulegioides, Mentha pulegium

Claimed benefits: improves breathing problems, digestive disorders

Potential harms: liver and kidney failure, nerve damage, convulsions

Usnic acid

Also called: beard moss, tree moss, usnea

Claimed benefits: weight loss, pain relief

Potential harms: liver injury

Yohimbe

Also called: Johimbi, Pausinystalia yohimbe, yohimbine, Corynanthe johimbi

Claimed benefits: treats low libido and erectile dysfunction, depression, obesity

Potential harms: raises blood pressure; causes rapid heart rate, headaches, seizures, liver and kidney problems, heart problems, panic attacks

Source: Consumer Reports Inc.

Consumer Reports is an independent, nonprofit organization that works side by side with consumers to create a fairer, safer, and healthier world. CR does not endorse products or services, and does not accept advertising. Read more at ConsumerReports.org.

[darkmaga-returns]

1. Ozempic and Wegovy are already transforming how we treat type 2 diabetes and obesity, and from next year another condition affecting millions of people worldwide might be added to the list: Alzheimer’s disease. Two clinical trials investigating semaglutide, the drug in Ozempic and Wegovy, as a therapy for early Alzheimer’s are expected to conclude in 2025. If the results are positive, it could mark a breakthrough in treating this intractable condition. Semaglutide belongs to a class of drugs that mimic a hormone called GLP-1. These GLP-1 agonists, as they are known, have wide-ranging effects, including regulating blood sugar, suppressing appetite and dampening inflammation. A growing body of evidence suggests that they may treat Alzheimer’s too. The most compelling research is a small trial involving 204 people with mild to moderate Alzheimer’s. (Source: newscientist.com)

2. Natasha Loder, Health editor, The Economist:

After decades of disappointment, efforts to create vaccines that can stimulate the immune system to fight cancer are showing renewed promise. Breakthroughs are possible in the coming year. The optimism stems from advances in mRNA technology and personalized medicine, and in particular from a melanoma vaccine called mRNA-4157, developed by Moderna and Merck, that is performing well in trials. In 2025 the FDA, America’s drugs regulator, could approve the vaccine. And in Britain the NHS’s Cancer Vaccine Launch Pad, a tie-up with BioNTech, a pioneer of covid vaccines, aims to fast-track thousands of patients into trials for mRNA-based personalized vaccines for colorectal, pancreatic and melanoma cancers. Personalized vaccines are tailored to a patient’s specific mutations, and aim to train the immune system to recognize and attack cancer cells based on their unique genetic make-up. First comes a biopsy, then the sequencing of the tumor, the identification of mutations likely to generate proteins that would be recognized by the immune system, and finally the manufacturing of a vaccine to target those markers. This can all be done within six weeks, thanks to advances in mRNA technology made during the pandemic, and to progress in artificial intelligence, which is used to predict the molecular markers most likely to stimulate the immune system into action. (Source: economist.com)

3. The dogs’ names are Mars, Moon and Pluto, and you might say their cancer-sniffing skills are out of this world. An experimental screening method that paired the dogs with artificial intelligence was able to detect the odor of cancer carried on patients’ breaths. The canine-AI duo was both highly accurate and highly sensitive, successfully spotting four types of cancer in 94 percent of cases, scientists report November 15 in Scientific Reports. What’s more, the screening worked just as well detecting early stage cancers as it did later stage cancers, says Assaf Rabinowicz, chief technology officer at SpotitEarly, the Israel-based company that developed the method. That’s crucial because early detection can substantially contribute to increasing cancer survival rates. Research paper is here. (Sources: nature.com, sciencenews.org)

4. U.S. Centers for Disease Control and Prevention (CDC):

CDC has sequenced the influenza viruses in specimens collected from the patient in Louisiana who was infected with, and became severely ill from HPAI A(H5N1) virus. The genomic sequences were compared to other HPAI A(H5N1) sequences from dairy cows, wild birds and poultry, as well as previous human cases and were identified as the D1.1 genotype. The analysis identified low frequency mutations in the hemagglutinin gene of a sample sequenced from the patient, which were not found in virus sequences from poultry samples collected on the patient’s property, suggesting the changes emerged in the patient after infection. (Source: cdc.gov)

[pharmaconferenceandexpo]

Advanced Drug Delivery Systems: Revolutionizing Modern Medicine

INTRODUCTION :

The field of medicine has witnessed groundbreaking innovations over the years, and one of the most significant advancements is in the realm of drug delivery systems. Traditional methods, such as oral tablets and injections, often fall short in ensuring precise drug targeting, controlled release, and reduced side effects. Advanced drug delivery systems (ADDS) have emerged as game-changers, offering sophisticated solutions that address these challenges. These systems leverage cutting-edge technologies to optimize therapeutic efficacy and improve patient outcomes.

What Are Advanced Drug Delivery Systems? Advanced drug delivery systems are engineered platforms designed to transport therapeutic agents to specific targets in the body with precision. Unlike conventional methods, ADDS can regulate the release of drugs over time, respond to specific stimuli, and bypass biological barriers. Examples include nanotechnology-based carriers, liposomes, polymeric systems, and implantable devices.

Key Features of Advanced Drug Delivery Systems

Targeted Delivery: ADDS ensures that drugs reach specific tissues or cells, minimizing exposure to healthy areas and reducing side effects.

Controlled Release: These systems can release drugs at a predetermined rate, maintaining optimal therapeutic levels over an extended period.

Biocompatibility: Many delivery platforms use materials that are non-toxic and biodegradable, ensuring safety and reducing environmental impact.

Stimuli-Responsive Mechanisms: Some systems can respond to external stimuli such as pH, temperature, or magnetic fields, enabling on-demand drug release.

Types of Advanced Drug Delivery Systems

Nanoparticle-Based Delivery: Nanoparticles, including liposomes and polymeric nanoparticles, enhance drug solubility, stability, and targeting.

Hydrogel Systems: These water-based networks are ideal for controlled drug release and are highly adaptable.

Transdermal Patches: These deliver drugs through the skin, offering a non-invasive alternative to injections.

Inhalable Drug Delivery: Used primarily for respiratory diseases, this system delivers medication directly to the lungs.

Implantable Devices: These devices provide long-term drug delivery and are especially useful for chronic conditions.

Applications of Advanced Drug Delivery Systems

Cancer Therapy: Targeted delivery minimizes the side effects of chemotherapy and enhances drug concentration at tumor sites.

Neurological Disorders: Advanced systems can cross the blood-brain barrier, allowing effective treatment of conditions like Alzheimer’s and Parkinson’s disease.

Gene Therapy: ADDS plays a crucial role in delivering genetic material safely and efficiently.

Vaccination: Controlled release mechanisms improve vaccine stability and efficacy.

Pain Management: Sustained-release formulations help in managing chronic pain without frequent dosing.

Challenges in Development

Despite their potential, the development of ADDS faces several hurdles:

Cost: The high cost of research, development, and production makes these systems expensive.

Regulatory Barriers: Strict guidelines for approval can delay market entry.

Complex Manufacturing: Advanced technologies require specialized equipment and expertise.

Patient Compliance: Implantable or wearable devices may not be well-received by all patients.

The Future of Drug Delivery Systems

The future of ADDS is incredibly promising, with ongoing research into integrating artificial intelligence, bioinformatics, and personalized medicine. Innovations such as CRISPR-based delivery, biodegradable implants, and multi-drug delivery platforms are set to transform healthcare further.

Conclusion

Advanced drug delivery systems represent a significant leap forward in modern medicine. By enhancing drug efficacy, minimizing side effects, and improving patient adherence, they address many limitations of traditional methods. While challenges remain, the ongoing evolution of ADDS promises a future where treatments are more precise, effective, and tailored to individual needs. The journey of advanced drug delivery is far from over, and its impact on global health is only beginning to unfold.

https://pharmacy.utilitarianconferences.com/registration

Hashtags for the Digital Pharmaceutical Innovations Advanced Drug Delivery Systems

#PharmaceuticalScience #NextGenDrugDelivery #PrecisionMedicine #Biopharmaceuticals #TargetedDrugDelivery #PharmacyAutomation #SmartPharmacy #PharmaTechInnovation #Biotechnology #PharmaDigitalTransformation #HealthcareInnovation #DigitalTherapeutics #DrugDevelopment #AdvancedPharmaTech #PharmaEngineering #MolecularMedicine #PersonalizedMedicine #PharmaceuticalIndustry #NanoTechnology #PharmaSolutions #TechInPharma #SmartTherapeutics #AdvancedPharmaScience #DrugDesign #PharmaAutomationTech #InnovationInPharma #PharmaResearch #DrugNanocarriers #PharmaceuticalEngineering #InnovativeDrugDelivery #SmartMedicalDevices #BioPharmaceuticalTech #DrugManufacturing #PharmaTechnologyInnovation #BiopharmaIndustry #IntelligentDrugDelivery #FutureOfPharmacy #PharmaAI #PharmacyTechInnovation #DrugTherapeutics

[seositetool]

Exosomes Are Being Hyped as a ‘Silver Bullet’ Therapy. Scientists Say No.

When human stem cells were discovered at the turn of the century, it sparked a frenzy. Scientists immediately dreamed of repairing damaged tissues due to aging or disease. A few decades later, their dreams are on the brink of coming true. The US Food and Drug Administration (FDA) has approved blood stem cell transplantation for cancer and other disorders that affect the blood and immune system.…

[onlymollygibson]

Im no expert but I'm a grad student working on a paper in this field.

Cancer is a bunch of diseases lumped togethet, so there will never be a one size fits all cure, just better and better treatments.

That said, the current treatments in the pipeline are incredible.

Cancer vaccines like the article talks about. Basically tumors exist because the immune system doesn't notice them as foreign or diseased, or it does notice but can't fight them because the tumor is actively suppressing the immune system. Cancer vaccines train your body's natural defenses to kill the cancer cells. Chefs kiss! Incredible science. Note that they surgically removed most of the tumor first in this trial, so it's a case of doing most of the work in surgery and letting your immune system do the cleanup.

Theyre finding in general that modern therapies like cancer vaccines or other immune boosting treatments work best in synchrony with other treatments (chemo, radiation, surgery) to get the last little bits that aren't taken out by surgery, or are resistant to chemo, etc. Immunotherapy doesn't necessarily do great at getting into tumors and wiping them out all on its own, but it's fantastic at killing the last remnants and prolonging remission or ensuring the cancer doesn't come back at all.

Some other cool immunotherapies and nanomedicines for cancer in the works (some are approved, some are still being developed.)

CAR T cells - remove white blood cells from the body, train them to attack the cancer and put them back in. Seriously look it up if you want your mind blown. This won the Nobel prize a few years back.

Nanocarriers for drugs- a big problem of cancer medicines is targeting - how do we kill the cancer while not harming the rest of the body too much. They're designing nano and micro scale encapsulation for drugs that get them to the cancer, either through direct chemical targeting or by taking advantage of the structural differences of tumors like blood vessels that are "leaky," meaning they let stuff through that non-tumor blood vessels don't. Some formulations are designed to decrease liver accumulation, or hide from the immune system. Early stages still but expect to see great things. They're trying everything from metal nanoparticles to cell membrane derived drug packaging to DNA origami. It's incredible.

Other immunotherapies: basically anything that activates the immune system to turn on the cancer. Everything from the aforementioned cancer vaccines, to cytokines (like hormones but for the immune system), to little "backpacks" made out of lipids that attach to tumor infiltrating lymphocytes (white blood cells that can get into the tumor) and deliver immune activating factors straight into the tumor by tagging along with cells that are going in anyways.

There's more but I have to analyze data now. Science is incredible!

The discovery represents a potential new way to recruit the immune system to fight treatment-resistant cancers using an iteration of mRNA technology and lipid nanoparticles, similar to COVID-19 vaccines, but with two key differences: use of a patient’s own tumor cells to create a personalized vaccine, and a newly engineered complex delivery mechanism within the vaccine.

Within 48 hours, the four human study participants showed remarkable results: their immune systems went into turbo cancer-destroying mode. And without surgery, radiation, or dangerous chemotherapy.

Folks, we may have a cure for cancer within your lifetime.

[marketsndata]

Japan Nutraceuticals Market Analysis 2030

The Japan Nutraceuticals Market was estimated at USD 13.65 billion in FY2023 and is anticipated to reach to USD 28.80 billion by FY2031 witnessing a CAGR of 9.78% during the forecast period FY2024-2031. There is little doubt that the Japanese market should be regarded as one of the “up-and-coming” markets for nutraceutical ingredients and functional foods, even though the term “nutraceutical” is not commonly used in Japan and is not familiar to the majority of Japanese consumers.

With a focus on relatively small servings of seasonal fruits and vegetables, as well as fish and shellfish, and rice as the main food, the traditional Japanese diet has been regarded as being highly nutritious. In the past, people consumed relatively little fat, largely from plant sources rather than animals. However, not all Japanese had access to the entire traditional cuisine on a daily basis, and food-related health problems were not unusual. Many people, especially women, were and still are concerned about their calcium and iron intake. The high incidence of stomach cancer in Japan was thought to be mostly due to the frequent eating of pickled and salted foods in the traditional diet.

Several traditional Japanese dietary ingredients have lately been found to provide additional health advantages beyond only providing nutrients. For instance, common dietary supplements include “beni koji” (red yeast) foods for lowering cholesterol, konnyaku non-caloric fibre for weight loss, and green tea catechins for their anti-caries and anti-cancer properties. The recent success of these traditional ingredients on the market has encouraged Japanese (and foreign) businesses to look more into the possible health advantages of other traditional culinary ingredients.

Increased Spending on Technical Innovations

Demand for these products increases as a result of rising costs for their technological advancements. Over-the-counter drug abuse has a negative impact on consumer lifestyle. Functional foods and beverages have solved this issue to great effect. The idea of functional food was developed in Japan in the 1980s and was given government approval to help the country’s citizens’ overall health. Functional foods are the most popular product category consumed by the public because they have benefits to health beyond supplying nutrients. They could lessen the chance of developing chronic illnesses and boost general health. Muesli is one of the most prevalent modern examples, as its soluble fibre decreases blood cholesterol levels. Diets can easily include whole grains, veggies, legumes, nuts, and fruits. They are unable to change consumers’ unhealthy eating habits, though.

Antioxidants included in fruits and vegetables help to fight against disease. Modified functional foods are also available that have been supplemented with probiotics, fibre, vitamins, or minerals to improve their nutritional value. Fortified cereals, fortified grains, fortified bread and pasta, and other fortified foods are examples of modified functional foods. In June 2021, a new patented process was developed by TCI Japan’s Science of Probiotics, which uses high-efficiency fermentation technology to put 100 billion live probiotics—roughly equal to the number of probiotics in ten bottles of typical lactic acid bacteria drinks—into each tiny glass bottle of drink. Modern technology can also be used to keep the drinks’ live bacterial populations at high levels.

Growing Dependence on Supermarkets and Hypermarkets

Supermarkets and hypermarkets have recently gained significance in busy consumers’ lifestyles because consumers tend to buy all of their monthly necessities from there. As opposed to visiting various stores, everything is offered under one roof, saving time. Due to the consumers’ fascination with the packaging and display format, supermarkets are crucial in encouraging excessive shopping. They often display informational materials, product descriptions, and nutritional details, helping customers understand the benefits and usage of various nutraceutical products. This education fosters consumer awareness and encourages them to make informed choices. Additionally, discounts at supermarkets are drawing customers in even more. By carefully reading the labels and contrasting the pricing of similar products, the buyer can choose from a variety of alternatives. Overall, the presence of nutraceuticals in supermarkets and hypermarkets in Japan not only provides convenient access for consumers but also facilitates product awareness, education, and promotion.

Government Regulations

In Japan, the term “nutraceuticals” is not commonly used. Instead, these products are typically classified as “foods for specified health uses” (FOSHU) or “foods with nutrient function claims” (FNFC). FOSHU and FNFC are categories created by the Japanese government to regulate functional foods and health claims. Manufacturers of FOSHU products must submit an application to the Consumer Affairs Agency (CAA) for approval. The application should include scientific evidence supporting the claimed health benefits and safety of the product. The CAA evaluates the application and grants approval if the product meets the necessary requirements. FOSHU products are permitted to make specific health claims, provided they have been approved by the CAA.

FNFC products, on the other hand, can make nutrient function claims without going through the same rigorous approval process as FOSHU. Nutraceutical products in Japan must comply with safety standards set by the Ministry of Health, Labour and Welfare (MHLW). Certain ingredients may be restricted or require special approval. Manufacturers are responsible for ensuring the safety of their products and conducting appropriate testing. Proper labelling is essential for nutraceutical products. Labels should clearly state the product’s category (FOSHU or FNFC), specific health claims (if applicable), and instructions for use. It is important to comply with the guidelines provided by the MHLW regarding labelling regulations.

Popularity of Western Ingredients

Western ingredients often bring a sense of novelty and exoticism to the Japanese market. Consumers are intrigued by ingredients that are not traditionally found in Japanese cuisine or culture. The introduction of Western ingredients in nutraceuticals provides a unique selling proposition and attracts consumers looking for something different and innovative. Western ingredients, such as specific herbs, botanicals, or superfoods, are often associated with various health benefits. They may offer antioxidant properties, immune system support, anti-inflammatory effects, or other wellness benefits. The inclusion of these Western ingredients in nutraceutical products expands the range of health benefits available to consumers, thereby driving demand. Japan has a rich history of cultural exchange with the West. The inclusion of Western ingredients in nutraceuticals reflects this cross-cultural appeal.

Japanese consumers are often receptive to products that blend traditional Japanese ingredients with Western ones, as it combines familiar elements with new flavours and health benefits. International nutraceutical brands and manufacturers often incorporate Western ingredients into their product formulations. The presence of these global brands in the Japanese market helps introduce and popularize Western ingredients among Japanese consumers. The trust and reputation associated with these brands contribute to driving the demand for nutraceuticals containing Western ingredients. Lutein, glucosamine, and Coenzyme Q10 sales are moving up the list of top sellers. For instance, Coenzyme Q 10 is becoming increasingly popular in Japan. According to Health Industry News (Tokyo), the industry has been increasing at a rapid rate for continuous years. Lutein is now a big market, but a few years ago, the majority of customers had never ever heard of it. Future Japan will undoubtedly be influenced by the West more.

Aging Population

Japan is known to have one of the most rapidly aging populations in the world. This demographic shift is primarily a result of low birth rates and a high life expectancy. Factors such as increased access to healthcare, advancements in medical technology, and improvements in living standards have contributed to longer lifespans. As people age, there is an increased focus on health maintenance and disease prevention. Older adults often seek ways to support their overall well-being and manage age-related health concerns. Nutraceuticals offer a convenient and accessible option for older individuals to supplement their diets with functional foods and dietary supplements that are specifically formulated to address their health needs. With advancing age, individuals may experience specific health issues such as joint health, cognitive decline, cardiovascular health, and immune system support. Older adults may face challenges in meeting their nutritional needs due to factors such as reduced appetite, diminished nutrient absorption, and dietary restrictions. Age-related conditions such as osteoporosis and joint discomfort are prevalent there among the aging population. Nutraceuticals that promote vitality, energy, and overall well-being are found attractive to this demographic. Products targeting energy support, stress management, and overall wellness are marketed to older adults seeking to enhance their quality of life and remain active as they age. For instance, in October 2021, to help older individuals’ memory abilities, Morinaga Milk Industry has introduced a new line of functional foods that contain its probiotic strain that has been professionally examined.

Impact of COVID-19

The COVID-19 pandemic has had a conflicting effect on the overall nutraceutical market. Demand for nutraceutical products increased as a result of increased health awareness and rising demand for immunity-boosting supplements. Although the absence of transportation and the limited supply chain had an influence on quarterly growth in 2020, many companies in the country altered their business hours and shortened them to enable employees to replenish goods and clean stores overnight. These elements hindered the market’s growth for functional foods and beverages. In order to boost people’s health and immunity, the demand for nutritional supplements and functional foods soared throughout the pandemic. There has been a shift in consumer behaviour towards purchasing supplements that increase immunity, lowering the likelihood of contracting an infection. Following the pandemic, preventative health measures have become more popular and demand for them is only growing. These have become a necessary component of consumers’ life as a result of the effects of the pandemic all over the world.

Download Sample Report

“Japan Nutraceuticals Market Assessment, Opportunities, and Forecast, FY2017-FY2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and assessment of the current scenario of the nutraceuticals market in Japan, industry dynamics and opportunities, and forecasts (FY2024-FY2031). Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc. 

Click here for full report-https://www.marketsandata.com/industry-reports/japan-nutraceuticals-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: info@marketsandata.com Website: https://www.marketsandata.com

[kristinahertzz]

Narcolepsy Therapeutics Market

Narcolepsy Therapeutics Market Size, Share, Trends: Jazz Pharmaceuticals plc Leads

Innovative Drug Delivery Systems Revolutionizing Narcolepsy Treatment

Market Overview:

The Narcolepsy Therapeutics market is projected to grow at a CAGR of 9.2% from 2024 to 2031. The market value is expected to reach XX USD by 2024 and YY USD by 2031. North America dominates the market, driven by a high prevalence of narcolepsy and advanced healthcare infrastructure. Key metrics include rising awareness about sleep disorders, increasing R&D investments in novel therapies, and growing adoption of combination therapies.

The market is expanding rapidly due to advancements in imaging technology, a rise in the prevalence of cancer and neurological illnesses, and the integration of PET/CT and PET/MR systems for greater diagnostic accuracy and efficiency.

DOWNLOAD FREE SAMPLE

Market Trends:

The emergence of novel drug delivery systems is an important trend in the Narcolepsy Therapeutics industry. These innovative systems aim to enhance the efficacy of existing medications and increase patient adherence. Extended-release formulations, sublingual, and intranasal administration techniques provide quick symptom relief and ease of use. Researchers are exploring targeted delivery systems that efficiently cross the blood-brain barrier, potentially offering more potent and specialized treatments for narcolepsy.

Market Segmentation:

The sodium oxybate segment dominates the Narcolepsy Therapeutics market due to its effectiveness in treating multiple narcolepsy symptoms, including excessive daytime sleepiness, cataplexy, and disrupted nighttime sleep. Sodium oxybate, marketed as Xyrem, is the only FDA-approved medication for severe daytime sleepiness and cataplexy in narcolepsy patients. Recent advancements, such as the development of Xywav, a low-sodium formulation, have expanded its market reach.

Market Key Players:

Jazz Pharmaceuticals plc

Harmony Biosciences Holdings, Inc.

Avadel Pharmaceuticals plc

Bioprojet

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Ltd.

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[amrutatbrc1]

Myelodysplastic Syndrome (MDS) Drugs Market 2024-2033 : Demand, Trend, Segmentation, Forecast, Overview And Top Companies 

The myelodysplastic syndrome (mds) drugs global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Myelodysplastic Syndrome (MDS) Drugs Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size - The myelodysplastic syndrome (mds) drugs market size has grown strongly in recent years. It will grow from $3.23 billion in 2023 to $3.47 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to aging population, advancements in targeted therapies, clinical trials, increased awareness.

The myelodysplastic syndrome (mds) drugs market size is expected to see strong growth in the next few years. It will grow to $4.69 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to genomic research, immunotherapies, global expansion of healthcare, biomarker identification. Major trends in the forecast period include personalized medicine, combinatorial therapies, symptom management, data sharing and collaboration.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-mds-drugs-global-market-report

The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Market Drivers - Rising exposure to cancer treatments, such as chemotherapy and radiation, is expected to boost the growth of the myelodysplastic syndrome (MDS) drug market going forward. Chemotherapy refers to using medications to eradicate cancer cells and radiation refers to a cancer treatment that uses high radiation doses to kill cancer cells and reduce tumors. Chemotherapy medications and radiation therapy harm the bone marrow's stem cells, which are in charge of making new blood cells; this damaging effect disturbs the natural balance of cell creation and results in the onset of MDS. Myelodysplastic syndrome (MDS) drugs offer several benefits in managing and treating MDS, a group of disorders characterized by abnormal production of blood cells in the bone marrow. For instance, according to ESTRO-HERO (Health Economics in Radiation Oncology) analysis by the European Society of Radiation Oncology (ESTRO), a Belgium-based organization, based on projected cancer distributions in 2025, there is an expected 16% increase in the number of radiotherapy treatment courses. Therefore, rising exposure to cancer treatments, such as chemotherapy and radiation, is driving the growth of the myelodysplastic syndrome (MDS) drugs market.

Market Trends - Major companies operating in the myelodysplastic syndrome (MDS) drugs market focus on developing new products to improve patient outcomes, meet specific customer needs and fit the ecosystem. Drug approvals such as venetoclax (VENCLEXTA) ensure that MDS drugs are safe and effective for managing this group of bone marrow disorders. For instance, in July 2021, AbbVie Inc., a US-based pharmaceutical company, received a Breakthrough Therapy Designation (BTD) for venetoclax (VENCLEXTA) in combination with azacitidine by the U.S. Food and Drug Administration (FDA) for the potential treatment of adult patients with untreated intermediate, high and very high-risk myelodysplastic syndromes (MDS). The unique feature of VENCLEXTA and VENCLYXTO is its capacity to attach to and inhibit the B-cell lymphoma-2 (BCL-2) protein. Additionally, BCL-2 inhibits the apoptosis, or natural death or self-destruction process of cancer cells, in several blood malignancies.

The myelodysplastic syndrome (mds) drugs market covered in this report is segmented –

1) By Drug Type: Chemotherapy; Immunomodulatory Drugs 2) By Route Of Administration: Oral; Parenteral 3) By Syndrome: Refractory Cytopenia With Multilineage Dysplasia; Refractory Anemia; Refractory Anemia With Ringed Sideroblasts 4) By End User: Hospitals; Clinics; Ambulatory Surgical Centers

Get an inside scoop of the myelodysplastic syndrome (mds) drugs market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13043&type=smp

Regional Insights - North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2023. The regions covered in myelodysplastic syndrome (MDS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Key Companies - Major players in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.

Table of Contents 1. Executive Summary 2. Myelodysplastic Syndrome (MDS) Drugs Market Report Structure 3. Myelodysplastic Syndrome (MDS) Drugs Market Trends And Strategies 4. Myelodysplastic Syndrome (MDS) Drugs Market – Macro Economic Scenario 5. Myelodysplastic Syndrome (MDS) Drugs Market Size And Growth ….. 27. Myelodysplastic Syndrome (MDS) Drugs Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: info@tbrc.info

Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model